secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0000950170-23-024920
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talaris CEO departs; CFO Fenton takes interim CEO role; strategic review underway
--------------------------------------------------------------------------------

- Scott Requadt left as CEO and President effective May 26, 2023; no disagreement cited.
- CFO Mary Kay Fenton appointed interim CEO and President, remaining CFO.
- Requadt to receive $50,000/month as strategic advisor through August 26, 2023.
- Company conducting strategic review including possible business combination or divestiture.
- Workforce reduction previously announced; no timetable set for review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/tals-20230526.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer